Drug intelligence / Profile preview

LPT-351

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-351 is an incrementally modified drug (IMD) or improved medical device/drug being developed by LitePharmTech. It is formulated as an ophthalmic solution for the treatment of various ophthalmic conditions. Currently in the preclinical stage of development, LPT-351 represents an optimized version of an existing therapeutic agent, designed to improve upon the safety, efficacy, or delivery characteristics of previous formulations. Specific details regarding its active pharmaceutical ingredient and precise mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on LPT-351.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-351.

Explore the full profile